Endogenous retrovirus

Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health

Retrieved on: 
Tuesday, January 12, 2021
Branches of biology, Molecular biology, Clinical medicine, Medicine, Virotherapy, Endogenous retrovirus, Retrovirus, Immunotherapy, Virus, Zidovudine

Human endogenous retroviruses (HERVs), remnants of ancient germ-line infections with exogenous retroviruses, are estimated to comprise up to 8% of the human genome.

Key Points: 
  • Human endogenous retroviruses (HERVs), remnants of ancient germ-line infections with exogenous retroviruses, are estimated to comprise up to 8% of the human genome.
  • The NIH will lead and be responsible for the manufacturing and clinical development of the CAR-T cell therapy candidate.
  • Adagene, Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.
  • Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

From Pig to Patient: XenoTherapeutics Completes First Cohort of Patients in First US Clinical Trial of Live-Cell Xenotransplant; Evidence of Safety and Efficacy Allows for Accelerated Patient Enrollment

Retrieved on: 
Thursday, November 5, 2020
Molecular biology, Branches of biology, Biology, Natural sciences, Biotechnology, Laboratory techniques, Animal testing, Life extension, Xenotransplantation, Endogenous retrovirus, Reverse transcription polymerase chain reaction, Polymerase chain reaction

As a result, the U.S. Food and Drug Administration (FDA) has agreed to permit accelerated patient enrollment; patients may now enroll in the trials second cohort simultaneously.

Key Points: 
  • As a result, the U.S. Food and Drug Administration (FDA) has agreed to permit accelerated patient enrollment; patients may now enroll in the trials second cohort simultaneously.
  • This first-in-human trial, conducted in partnership with the Massachusetts General Hospital, is expected to be completedby the end of 2020.
  • Especially notable, post-operative RT-PCR evaluation of all patient samples showed no evidence of detection of the porcine endogenous retrovirus.
  • XenoTherapeutics has pioneered the clinical advancement of xenotransplantation by initiating human trials for the first-in-human, live-cell xenotransplantation surgery with Xeno-Skin.

Qihan Biotech Publishes First Clinical Xenotransplantation Prototype, ‘Pig 3.0’, in Nature Biomedical Engineering

Retrieved on: 
Monday, September 21, 2020
Oncology, Health, Surgery, Genetics, Research, Science, Biotechnology, Medical specialties, Clinical medicine, Medicine, Animal testing, Molecular biology, Organ transplantation, Life extension, Xenotransplantation, Endogenous retrovirus, Perv, Allotransplantation, Domestic pig, Qihan Biotech, Qihan’s High-Throughput, Multiplexable Genome Editing Platform, Qihan’s Immune Privileged Technology Platform

The results, which were published today in Nature Biomedical Engineering, show enhanced immunocompatibility of xenogeneic organs and full eradication of porcine endogenous retroviruses (PERV).

Key Points: 
  • The results, which were published today in Nature Biomedical Engineering, show enhanced immunocompatibility of xenogeneic organs and full eradication of porcine endogenous retroviruses (PERV).
  • Qihan Biotech is committed to developing novel cell and organ therapies which can be available to patients worldwide.
  • Currently, the clinical applicability of allogeneic cell therapies and organ xenotransplantation is limited by molecular incompatibilities between the transplant and the recipient.
  • Qihan is also a pioneer in engineering extensively genome-modified pigs as bioreactors to grow xenogeneic cells, tissues and organs for safe and effective clinical applications.